Triglyceride-Glucose Index is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients with HBV-Related Liver Cirrhosis

References

• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-1
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Zhu D-M, Xie J, Ye C-Y, et al. Risk of hepatocellular carcinoma remains high in patients with HBV-related decompensated cirrhosis and long-term antiviral therapy. Can J Gastroenterol Hepatol. 2020;2020:8871024. doi:10.1155/2020/8871024
   PubMed Web of Science ®Google Scholar
• Mao H-D, Zheng S-Q, Yang S-H, et al. A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study. PeerJ. 2023;11:e15014. doi:10.7717/peerj.15014
   PubMed Web of Science ®Google Scholar
• Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol. 2023;14:1149239.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–E223. doi:10.1152/ajpendo.1979.237.3.E214
   PubMed Web of Science ®Google Scholar
• Kim JH, Sinn DH, Gwak G-Y, et al. Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. J Gastroenterol Hepatol. 2017;32(5):1100–1106. doi:10.1111/jgh.13647
   PubMed Web of Science ®Google Scholar
• Imai K, Takai K, Hanai T, et al. Homeostatic model assessment of insulin resistance for predicting the recurrence of hepatocellular carcinoma after curative treatment. Int J Mol Sci. 2019;20(3):605. doi:10.3390/ijms20030605
   PubMed Web of Science ®Google Scholar
• Ding X, Wang X, Wu J, et al. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol. 2021;20(1):76. doi:10.1186/s12933-021-01268-9
   PubMed Web of Science ®Google Scholar
• Wei Y, Guo J. High triglyceride-glucose index is associated with poor prognosis in patients with acute pancreatitis. Dig Dis Sci. 2023;68(3):978–987. doi:10.1007/s10620-022-07567-9
   PubMed Web of Science ®Google Scholar
• Xue Y, Xu J, Li M, et al. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: triglyceride glucose index-related parameters. Front Endocrinol. 2022;13:951689. doi:10.3389/fendo.2022.951689
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang Q, Wang Y, et al. Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer. BMC Cancer. 2022;22(1):1007. doi:10.1186/s12885-022-10100-w
   PubMed Web of Science ®Google Scholar
• Shi H, Zhou L, Yang S, Zhou H. The relationship between Triglyceride and glycose (TyG) index and the risk of gynaecologic and breast cancers. Clin Nutr ESPEN. 2022;51:345–352.
   PubMed Web of Science ®Google Scholar
• Wang F, He T, Wang G, et al. Association of triglyceride glucose-body mass index with non-small cell lung cancer risk: a case-control study on Chinese adults. Front Nutr. 2022;9:1004179. doi:10.3389/fnut.2022.1004179
   PubMed Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases, C.M.A. and C.M.A. Chinese Society of Hepatology. 中华医学会感染病学会分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938–961. Chinese. doi:10.3760/cma.j.issn.1007-3418.2019.12.007
   PubMedGoogle Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845. doi:10.2307/2531595
   PubMed Web of Science ®Google Scholar
• Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroenterol Hepatol. 2014;12(1):117–119. doi:10.1016/j.cgh.2013.07.040
   PubMed Web of Science ®Google Scholar
• Tu JF, Ding Y-H, Ying X-H, et al. Regulatory T cells, especially ICOS(+) FOXP3(+) regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep. 2016;6(1):35056. doi:10.1038/srep35056
   PubMed Web of Science ®Google Scholar
• Wang J-H, Li W-F, Yong -C-C, et al. Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. Sci Rep. 2021;11(1):6041. doi:10.1038/s41598-021-85431-y
   PubMed Web of Science ®Google Scholar
• Baumeister SE, Schlesinger S, Aleksandrova K, et al. Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study. J Hepatol. 2019;70(5):885–892. doi:10.1016/j.jhep.2018.12.014
   PubMed Web of Science ®Google Scholar
• Ni XC, Yi Y, Fu Y-P, et al. Role of lipids and apolipoproteins in predicting the prognosis of hepatocellular carcinoma after resection. Onco Targets Ther. 2020;13:12867–12880. doi:10.2147/OTT.S279997
   PubMed Web of Science ®Google Scholar
• Choe JW, Hyun JJ, Kim B, et al. Influence of metabolic syndrome on cancer risk in HBV carriers: a nationwide population based study using the national health insurance service database. J Clin Med. 2021;10(11):2401. doi:10.3390/jcm10112401
   PubMed Web of Science ®Google Scholar
• Cho Y, Cho EJ, Yoo -J-J, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers. 2021;13(7):1599. doi:10.3390/cancers13071599
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang X, Zhang W, et al. The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in Mainland China. Cancer Epidemiol Biomarkers Prev. 2019;28(12):2038–2046. doi:10.1158/1055-9965.EPI-19-0303
   PubMed Web of Science ®Google Scholar
• Zhang S, Cheng Z-M, Yu J-L, et al. Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride production. Cancer Med. 2021;10(19):6795–6806. doi:10.1002/cam4.4209
   PubMed Web of Science ®Google Scholar
• Ono M, Fujita K, Kobayashi K, et al. Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma. Hepatol Res. 2023;53(7):579–594. doi:10.1111/hepr.13912
   PubMed Web of Science ®Google Scholar
• Tsai PC, Kuo H-T, Hung C-H, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2023;78(2):281–292. doi:10.1016/j.jhep.2022.09.019
   PubMed Web of Science ®Google Scholar